Aspirin and serum estrogens in postmenopausal women: a randomized controlled clinical trial.

ABSTRACT: Epidemiologic studies suggest a reduced risk of breast cancer among women who use aspirin. A plausible mechanism is through aspirin's effect on estrogens, possibly mediated through interference with estrogen synthesis via reduction in inflammation, which is increased in adipose tissues, including breast. In a randomized placebo-controlled trial, we evaluated the effects of six-month administration of 325 mg/day aspirin on serum estrogens (estradiol, estrone, free estradiol, and bioavailable estradiol) and sex hormone-binding globulin (SHBG) in 144 healthy postmenopausal women. Eligible participants, recruited 2005-2007, were not taking nonsteroidal anti-inflammatory medication, including aspirin >2 times/week or menopausal hormone therapy, and had a Breast Imaging-Reporting and Data System

SUBMITTER: Duggan C 

PROVIDER: S-EPMC4155012 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature